AstraZeneca stock plunges after late-stage heart drug trial misses its target
The British drugmaker lost roughly $27 billion in market value after Wainua failed to reduce cardiovascular deaths and recurring heart events
Overview
The British drugmaker lost roughly $27 billion in market value after Wainua failed to reduce cardiovascular deaths and recurring heart events
Source
Originally published at qz.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.
